skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Biomarkers and Surrogate Endpoints for Normal-Tissue Effects of Radiation Therapy: The Importance of Dose-Volume Effects

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2];  [3];  [4];  [5];  [6]
  1. Cross Cancer Institute and University of Alberta, Edmonton, Alberta (Canada)
  2. Mallinckrodt Institute of Radiology, Washington University Medical Center, St. Louis, MO (United States)
  3. Radiation Therapy Oncology Group, Philadelphia, PA (United States)
  4. Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA (United States)
  5. University of Rochester Medical Center, Rochester, NY (United States)
  6. Department of Radiation Oncology, Mount Sinai School of Medicine and NYU School of Medicine, New York, NY (United States)

Biomarkers are of interest for predicting or monitoring normal tissue toxicity of radiation therapy. Advances in molecular radiobiology provide novel leads in the search for normal tissue biomarkers with sufficient sensitivity and specificity to become clinically useful. This article reviews examples of studies of biomarkers as predictive markers, as response markers, or as surrogate endpoints for radiation side effects. Single nucleotide polymorphisms are briefly discussed in the context of candidate gene and genomewide association studies. The importance of adjusting for radiation dose distribution in normal tissue biomarker studies is underlined. Finally, research priorities in this field are identified and discussed.

OSTI ID:
21372144
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 76, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2009.08.076; PII: S0360-3016(09)03579-2; Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; ISSN 0360-3016
Country of Publication:
United States
Language:
English